Lowest Price Guaranteed From USD 4,799
Companies Covered
86
Pages
220
View Count
11499
The global bacteriophage therapy market, also known as phage therapy market, is estimated to be USD 74 million in 2022, growing at a CAGR of 8% during the forecast period. Antimicrobial resistance (AMR) has been identified as one of the greatest threats to public health. According to the Centers of Disease Control and Prevention, more than 2.8 million cases of AMR infections are identified in the United States on an annual basis, leading to death of more than 35,000 people. Further, World Health Organization (WHO) has estimated that, by 2050, the increasing burden of such infections is expected to increase the healthcare expenditure by USD 1.2 trillion, annually. To address this situation, WHO has developed a global action plan for raising public awareness, reducing the incidence of infections, and optimizing the use of antimicrobial drugs, paving the way for the development of alternative anti-infectious modalities. One such example of these modalities includes bacteriophage therapy, also known as phage therapy. These therapeutics have been used in healthcare for over a century, providing an alternative approach to target the disease-causing multi-drug resistant bacteria; however, their use has been limited. With the growing need for therapies targeting AMR infections, phage therapy is now gaining more traction. These therapeutics tend to cause minimal drug toxicity, replicate themselves at the site of action, have reduced side-effects, and have the potential to self-decompose when the infection causing bacteria have been exterminated. Given the afore-mentioned advantages of bacteriophage therapy and promising insights from the ongoing research, various clinical trials have been registered for the clinical evaluation of bacteriophage therapies.
![]() |
![]() |
![]() |
The “Bacteriophage Therapy Market - Distribution by Therapeutic Area (Infectious Diseases, Oncological Disorders, and Other Disorders), Route of Administration (Oral, Topical, Rectal and Intravenous), and Geography (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study on the current market landscape and market size, offering an informed opinion on the likely evolution and future opportunities associated with the phage therapy market. The study underlines an in-depth analysis, highlighting the key drivers and the market trends related to this evolving segment of the pharmaceutical industry.
The global bacteriophage therapy market is valued at USD 74 million in 2022, mainly driven by the sales of marketed phage therapeutics. Russia, Poland and Republic of Georgia currently employ phage therapy in their routine medical practice. There are multiple challenges restraining the market growth of the global phage therapy market including the lengthy process of identifying the right phage against the patient’s bacterial isolate, concern with the stability of phage preparations during storage and transportation, and the possibility of developing phage resistance. The industry is developing strategies to overcome these challenges and we expect the phage therapy market size to witness expansion as the wider adoption of this therapeutic approach is successful to provide an effective solution for the increasing multi-drug-resistant bacterial infections. The market for bacteriophage therapy will grow at a CAGR of more than 8% during the forecast period.
The therapeutic efficacy of bacteriophages against infections caused by multi-drug resistant pathogens (such as, Staphylococcus aureus, Escherichia coli, Klebsiella pneumonia and Pseudomonas aeruginosa) has been demonstrated for human use. They are used as an anti-infective treatment for conditions such as respiratory infections, urinary tract infection, and rhinosinusitis. However, some drug developers are also evaluating the efficacy of phage therapy in indications such as ulcers as well as cancer. As an anticancer agent, the bacteriophages are used to deliver apoptotic agents or oligonucleotide drugs to cancer cells. However, the use of bacteriophage for treatment of diseases beyond infectious diseases is in early stages of development and more research efforts will be required to prove their potential in these therapeutic areas.
In 1940s, attributing to the improper ways of storage and purification processes used, along with the selective nature of various phages, which could not be recognized at that time, the US and majority of the Europe abandoned the use of these phage therapies, marking them as a failure. However, phage therapy has made a comeback to the attention of pharmaceutical industry in North America and Europe owing to the focus on antimicrobial resistance. In June 2018, the first phage therapy centre - Center for Innovative Phage Applications and Therapeutics (IPATH) - opened in UC San Diego School of Medicine with the aim to provide phage therapy to patient with multi-drug resistant infections under FDA’s compassionate use program. Additionally, in March 2021, the National Institutes of Health (NIH) awarded USD 2.5 million in grants to 12 institutes around the world, showing their support for the phage therapy. Companies headquartered in the US are evaluating their candidates in multiple clinical trials and collaborating for research and development of phage therapeutics. The future of phage therapy in North America looks promising with the market size likely to witness growth in the long-term as phage therapies receive FDA approval and acceptance amongst the physician community.
With the widespread participation of stakeholders in the research and development of bacteriophage therapy, clinical studies evaluating this drug class have increased at a growth rate of more than 30% over the last few years. Moreover, the volume of affiliated scientific literature (2,200+ related publications since 2018) has also increased, demonstrating the growing popularity of phage therapy and related technologies. Given the encouraging results, this domain has piqued the interest of many private and public investors who have invested more than USD 1 billion over the last few years. With increasing R&D efforts, promising clinical data, and financial support from investors, we anticipate the phage therapy market to witness notable market growth during the forecast period.
![]() |
![]() |
![]() |
Several recent developments have taken place in the field of bacteriophage therapy. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
Scope of the Report
Key Report Attributes | Details | |
Forecast Period |
2023 – 2035 |
|
Market Size 2022 |
USD 74 million |
|
CAGR |
8% |
|
Base Year | 2022 | |
Target Therapeutic Area |
Infectious Diseases, Oncological Diseases, Other Disorders |
|
Route of Administration |
Oral Route, Topical Route, Rectal Route, Intravenous Route |
|
Geographical Regions |
North America, Europe, Asia-Pacific |
Amongst other elements, the report includes:
One of the key objectives of the research report was to estimate the current market size and potential market growth opportunities, over the forecast period. Based on various parameters, such as target patient population, region specific adoption rates, and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market in the short to mid-term and long term, for the period 2022-2035. In order to evaluate the current and future opportunity associated with the bacteriophage therapy market, our year-wise projections have been segmented based on several relevant parameters such as, target therapeutic area (infectious diseases, oncological disorders, and other disorders), route of administration (oral, topical, rectal and intravenous), and geographical region (North America, Europe, Asia Pacific, and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market’s evolution.
![]() |
![]() |
![]() |
The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
All actual figures have been sourced and analysed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.